Accuzyme

Accuzyme™

Molecular biology A thermostable enzyme possessing 5 -3  DNA polymerase and 3 -5  high-fidelity proof-reading exonuclease activities, producing blunt-ended amplicons of up to 5Kb in length, optimised for use in a detergent-free system.
Wound care A topical ointment containing urea and papain, which is FDA approved for debriding wounds.

Accuzyme™

Wound care An enzymatic ointment for debriding acute and chronic wounds. See Wound care.
References in periodicals archive ?
Esta reaccion fue llevada a cabo con 100 ng de ADN genomico en una reaccion de 25 [micron]L de volumen final conteniendo 1x mezcla master (Promega)/ mezcla Accuzyme (Bioline), 0,4 pmol de cada cebador.
Estudio clinico y molecular del sindrome de Noonan
16 [micro]L Accuzyme DNA polymerase (Bioline: Randolph, MA), and 0.
Comparison of short-term preservation and assay methods for the molecular detection of Wolbachia in the Mediterranean flour moth Ephestia kuehniella
We initially applied Accuzyme ointment, covered it with Telfa pads, and wrapped it in Kerlix.
A disfigured foot with ulcer: our patient had double trouble: an abnormally shaped foot and a large wound on the plantar surface
Prior authorization for ACCUZYME and PANAFIL is not required.
ACCUZYME Ointment, Papain, Urea, 30 gram tube (NDC# 00064-1000-01) and PANAFIL Ointment, Papain, Urea, Chlorophyllin Copper Complex Sodium, 30 gram tube (NDC# 00064-3410-30) are readily available at pharmacies and drug wholesalers in California and nationwide.
The sole source status for ACCUZYME Ointment became effective December 2003, and sole source status for PANAFIL Ointment took effect March 2004.
ACCUZYME is a debriding ointment indicated for treatment of necrotic tissue and liquefication of slough in acute and chronic lesions such as pressure ulcers, varicose and diabetic ulcers, burns, postoperative wounds, pilonidal cyst wounds, carbuncles and miscellaneous traumatic or infected wounds.
Medi-Cal Announces Labeler Code Exclusivity For ACCUZYME Ointment And PANAFIL Ointment by HEALTHPOINT, Ltd
Accuzyme is an enzymatic debriding ointment used to treat wounds, pressure ulcers and burns by removing dead tissue without harming living tissue.
According to HEALTHPOINT, the suit against Stratus was instituted when the company learned that patients were being prescribed Accuzyme and Panafil, yet Kovia and Ziox were substituted without a determination that the substituted products were pharmaceutically equivalent, therapeutically equivalent or bioequivalent.
HEALTHPOINT's victory shows that Stratus's use of terms and phrases like "generic," "generic alternative," "branded generic," "bioequivalent," or "equivalent" wrongly suggested that Kovia is interchangeable with Accuzyme and that Ziox is interchangeable with Panafil.
The court said that there had been no evidence submitted to show that there is a current drug product that has demonstrated pharmaceutical equivalence, therapeutic equivalence, bioequivalence, or generic equivalence to Accuzyme or Panafil.
HEALTHPOINT Prevails in Lawsuit: Jury Finds Stratus Acted with Malice, Was Guilty of False Advertising and Misappropriation; Awards HEALTHPOINT $3 Million
Conversely, ACCUZYME is marketed solely as an enzymatic debriding agent for necrotic wounds.
HEALTHPOINT Tissue Management Division Receives Prestigious Frost & Sullivan Marketing Strategy Award
Medical browser ?
Full browser ?